[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1375 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 1375
To allow the Secretary of Health and Human Services to deny approval of
a new drug application for an opioid analgesic drug on the basis of
such drug not being clinically superior to other commercially available
drugs.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
March 3, 2023
Mr. Trone (for himself and Mr. Meuser) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To allow the Secretary of Health and Human Services to deny approval of
a new drug application for an opioid analgesic drug on the basis of
such drug not being clinically superior to other commercially available
drugs.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Ensuring the FDA Fully Examines
Clinical Trial Impact and Vitalness before Endorsement Act'' or the
``EFFECTIVE Act''.
SEC. 2. REQUIREMENT FOR APPROVAL OF NEW OPIOID ANALGESICS.
Section 505(c) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355(c)) is amended by adding at the end the following:
``(6) Notwithstanding any other provision of this section, the
Secretary may deny approval of an application submitted under
subsection (b) for an opioid analgesic drug if the Secretary determines
that such drug does not provide a significant advantage, in terms of
greater safety or effectiveness, compared to an appropriate comparator
drug, as determined by the Secretary.''.
<all>